| Literature DB >> 25548153 |
Yun Ji1, Claudia Wrzesinski2, Zhiya Yu2, Jinhui Hu3, Sanjivan Gautam3, Nga V Hawk3, William G Telford3, Douglas C Palmer2, Zulmarie Franco2, Madhusudhanan Sukumar2, Rahul Roychoudhuri2, David Clever2, Christopher A Klebanoff2, Charles D Surh4, Thomas A Waldmann5, Nicholas P Restifo2, Luca Gattinoni1.
Abstract
Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic "cytokine sinks." These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8(+) T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic γc cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.Entities:
Keywords: adoptive immunotherapy; homeostatic cytokines; lymphodepletion; microRNA-155
Mesh:
Substances:
Year: 2014 PMID: 25548153 PMCID: PMC4299215 DOI: 10.1073/pnas.1422916112
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205